Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
作者信息
Mazza Mario Gennaro, Vai Benedetta, De Picker Livia, Benedetti Francesco, Zanardi Raffaella
机构信息
Psychiatry and Clinical Psychobiology, Division of Neuroscience, Dipartimento di Neuroscienze Cliniche, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
出版信息
Drugs. 2022 Feb;82(3):349-351. doi: 10.1007/s40265-022-01682-7. Epub 2022 Feb 12.
Abstract
摘要
相似文献
1
Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
Drugs. 2022 Feb;82(3):349-351. doi: 10.1007/s40265-022-01682-7. Epub 2022 Feb 12.
2
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
3
Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".
Drugs. 2022 Feb;82(3):353-354. doi: 10.1007/s40265-022-01681-8. Epub 2022 Feb 12.
4
Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase.
Pharmacopsychiatry. 2022 Jan;55(1):57. doi: 10.1055/a-1641-0357. Epub 2021 Sep 23.
5
Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.
Am J Ther. 2022;29(3):e298-e304. doi: 10.1097/MJT.0000000000001496. Epub 2022 Mar 31.
6
Fluvoxamine for COVID-19?
Med Lett Drugs Ther. 2021 May 3;63(1623):69-70.
7
Fluvoxamine for Acute COVID-19 Infection: Weak Hypothesis, Predictable Failure.
Am J Ther. 2022;29(3):e342-e343. doi: 10.1097/MJT.0000000000001502. Epub 2022 Mar 29.
8
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
9
Fluvoxamine for the treatment of COVID-19.
Lancet Glob Health. 2022 Mar;10(3):e330. doi: 10.1016/S2214-109X(22)00003-1.
10
Fluvoxamine for the treatment of COVID-19.
Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1.
引用本文的文献
1
Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".
Drugs. 2022 Feb;82(3):353-354. doi: 10.1007/s40265-022-01681-8. Epub 2022 Feb 12.
本文引用的文献
1
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
2
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
3
Rapid response to selective serotonin reuptake inhibitors in post-COVID depression.
Eur Neuropsychopharmacol. 2022 Jan;54:1-6. doi: 10.1016/j.euroneuro.2021.09.009. Epub 2021 Oct 9.
4
Psychiatric and neuropsychiatric sequelae of COVID-19 - A systematic review.
Brain Behav Immun. 2021 Oct;97:328-348. doi: 10.1016/j.bbi.2021.07.018. Epub 2021 Jul 30.
5
Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysis.
JAMA Psychiatry. 2021 Oct 1;78(10):1079-1091. doi: 10.1001/jamapsychiatry.2021.1818.
6
Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.
Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17.
7
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.
Open Forum Infect Dis. 2021 Feb 1;8(2):ofab050. doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.
8
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.
9
Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?
J Neuroimmune Pharmacol. 2021 Mar;16(1):1-3. doi: 10.1007/s11481-020-09966-z. Epub 2020 Oct 26.
10
Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors.
Brain Behav Immun. 2020 Oct;89:594-600. doi: 10.1016/j.bbi.2020.07.037. Epub 2020 Jul 30.
Zotero 插件